ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

Additionally, AbbVie's oncology segment benefited from solid sales of Venclexta and the newly acquired Elahere, reinforcing positive investor sentiment. For the current fiscal year, ending in ...

We'll unveil the top 10 clothing brand logos that have conquered the fashion industry and left an indelible mark on our collective consciousness. If there's one thing that can instantly grab our ...

It’s worth noting that BMS’ decision to exit the deal comes shortly after AbbVie secured full FDA approval for its FRα-directed ADC candidate – Elahere (mirvetuximab soravtansine ...

Ovarian cancer is a relatively manageable malignancy when diagnosed at an early stage, but late-stage detection almost always translates into a poor prognosis. Researchers have been vigorously ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

patients who may benefit from ELAHERE ; LightCycler PRO System, a qPCR system designed to deliver accuracy and flexibility to research and clinical diagnostic laboratories; and cobas pulse, a ...

PARP inhibitors prevent cancer cells from repairing their DNA. Elahere (molecular name mirvetuximab) is an FDA-approved targeted therapy providing much-needed hope for patients with platinum-resistant ...

Bonnie Qin, PhD, assistant professor at Rutgers Cancer institute, discusses factors that may influence adherence to dietary guidelines and improve survival for Black women with ovarian cancer.